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ABSTRACT
Adult mesenchymal stem cells (MSCs) are immunoprivileged cells due to the low expression of
major histocompatibility complex (MHC) II molecules. However, the expression of MHC mole-
cules in human-induced pluripotent stem cells (iPSCs)-derived MSCs has not been investigated.
Here, we examined the expression of human leukocyte antigen (HLA) in human MSCs derived
from iPSCs, fetuses, and adult bone marrow (BM) after stimulation with interferon-c (IFN-c),
compared their repair efficacy, cell retention, inflammation, and HLA II expression in immune
humanized NOD Scid gamma (NSG) mice of hind limb ischemia. In the absence of IFN-c stimula-
tion, HLA-II was expressed only in BM-MSCs after 7 days. Two and seven days after stimulation,
high levels of HLA-II were observed in BM-MSCs, intermediate levels were found in fetal-MSCs,
and very low levels in iPSC-MSCs. The levels of p-STAT1, interferon regulatory factor 1, and class
II transactivator exhibited similar phenomena. Moreover, p-STAT1 antagonist significantly
reversed the high expression of HLA-II in BM-MSCs. Compared to adult BM-MSCs, transplanting
iPSC-MSCs into hu-PBMNC NSG mice revealed markedly more survival iPSC-MSCs, less inflam-
matory cell accumulations, and better recovery of hind limb ischemia. The expression of HLA-II
in MSCs in the ischemia limbs was detected in BM-MSCs group but not in iPSC-MSCs group at 7
and 21 days after transplantation. Our results demonstrate that, compared to adult MSCs,
human iPSC-MSCs are insensitive to proinflammatory IFN-c-induced HLA-II expression and iPSC-
MSCs have a stronger immune privilege after transplantation. It may attribute to a better thera-
peutic efficacy in allogeneic transplantation. STEM CELLS 2015; 00:000–000
SIGNIFICANCE STATEMENT
Allogenic transplantation of MSCs derived from bone marrow has been used clinically in graft
versus host disease, multiple sclerosis, diabete or ulcerative colitis, crohn’s disease and the
other diseases. Here we identified that human MSCs derived from iPS Cells exhibited poor
immunogenicity after IFN-c stimulation in vitro and exerted more cell retention, less inflamma-
tion and better efficacy in a model of limb ischemia in immune humanized mice compared to
BM-MSCs. It suggests that these cells may have more potential clinical implications with a
lower risk of rejection and a better therapeutic efficacy in allogenic transplantation.
INTRODUCTION
Mesenchymal stem cells (MSCs) have attracted
attention due to their potential use in trans-
plantation for the treatment of regenerative
medicine and immune diseases. MSCs have
been demonstrated to be poor stimulators of
an in vitro allogeneic T-cell response and fail
to induce the activation of allogeneic T cells
[1]. Transplanted MSCs should not trigger a
strong host inflammatory response [2]. The
implantation of allogeneic, major histocompati-
bility complex (MHC)-mismatched MSCs into
baboons has been well tolerated in most ani-
mals [3, 4]. Clinical studies have shown that
allogenic MSCs can be transplanted into chil-
dren with imperfecta with beneficial effects
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and without rejection [5]. Allogenic bone marrow (BM)-MSC
infusions into patients have shown to exert benefits in clinical
trials of graft-versus-host disease (GvHD) [6, 7], type 2 diabe-
tes [8], and systemic lupus erythematosus [9]. The cotrans-
plantation of autologous MSCs and hematopoietic stem cells
(HSCs) may enhance HSC engraftment [10]. These findings
suggest that even human leukocyte antigen (HLA)-mismatched
MSCs can be used in many novel applications in clinical stem
cell-based therapies.
The allogenic response is usually mediated by the HLA
and it is expected that the transplantation of cells that do not
express HLA-II antigens may minimize the alloreactivity risk.
MSCs express low levels of MHC class I molecules on their
surface but lack the expression of MHC class II and the costi-
mulatory molecules CD80 (B7-1), CD86 (B7-2), and CD40 [1,
11], which may limit immune recognition. Transplanted MSCs
differentiate in vivo and are also exposed to proinflammatory
cytokines during infection and inflammation. MSCs are treated
with interferon-c (IFN-c), a proinflammatory cytokine, to rep-
resent the “worst case scenario,” which corresponds to the
implantation of MSCs into sites of inflammation [12]. IFN-c is
known to increase the cell surface expression of MHC mole-
cules in antigen-presenting cells (APCs) and has been demon-
strated to upregulate MHC-II molecules in MSCs.
Most of the above-mentioned studies focused on adult
MSCs, such as MSCs derived from the BM. We recently suc-
ceeded in inducing MSCs from human-induced pluripotent
stem cell (iPSCs) [13]. We found that iPSC-MSCs express well-
known adult BM-MSC markers, display the potential for adi-
pogenesis, osteogenesis, and chondrogenesis, and prevent air-
way allergic inflammation after xenogenic transplantation
[14]. Furthermore, iPSC-MSCs display a higher capacity of
both cell proliferation and repair of tissue ischemia compared
with their adult BM-MSC counterparts [13]. However, the
MHC expression kinetics and immunogenicity of iPSC-MSCs
have not yet been investigated.
The aim of this study was to characterize the immunologi-
cal properties and patterns of both HLA class I and II and the
possible mechanisms activated in MSCs derived from different
origins after exposure to IFN-c. Moreover, the cell retention,
relative immune responses, HLA II levels in MSCs, and repair
efficiency of human iPSC-MSCs on the transplantation sites
were examined in a model of hind limb ischemia in immune
humanized mice. Our study demonstrated that, compared to
adult MSC, human iPSC-MSCs express lower levels of HLA-II
even stimulated by inflammatory cytokines (i.e., IFN-c) and
exhibit higher cell survival as well as lower immune responses
after transplantation in mice, which make them attractive can-
didates for clinical application in allogeneic transplantation.
MATERIALS AND METHODS
Preparation of Human iPSC-MSCs, Fetal-MSCs, and
BM-MSCs
Two independent clones of iPSCs were differentiated into
MSCs according to our previous study [15]. iMR90-iPSC-MSCs
10 were generated from iPSC-iMR90-5 (WiCell Research Insti-
tute, Madison, WI, www.wicell.org) [13]. The N1-iPSC-MSC
clone was prepared from iPSCs reprogrammed from human
fibroblast cells [16]. The details are presented in Supporting
Information Methods. The iPSC-MSCs were morphologically
highly similar to BM-MSCs, had the capacity to differentiate
into osteoblasts, adipocytes, and chondroblasts, and exhibited
a similar expression profile of surface antigens.
Human MSCs derived from fetal BM (fMSCs, passage 2,
catalog No. HUXMF-01001) and BM-MSCs (passage 2, catalog
No. HUXMA-01001) derived from the BM of healthy adults
were purchased from Cyagen Biosciences, Inc. (Suzhou,
JiangSu, People’s Republic of China). The cells were separately
cultured with human umbilical cord-MSC growth medium
with human umbilical cord MSC basal medium, 10% fetal
bovine serum, 1% glutamine, and 1% penicillin-streptomycin
(Cat. No. HUXUC-90011, Cyagen Biosciences, Inc., Suzhou,
JiangSu, China, www.cyagen.com.cn) or human BM-MSC
growth medium with human BM-MSC basal medium, 10%
fetal bovine serum, 1% glutamine, and 1% penicillin-
streptomycin (Cat. No. HUXMA-90011, Cyagen Biosciences,
Inc., Suzhou, JiangSu, China, www.cyagen.com.cn).
Stimulation of MSCs
Previous studies have shown that the expression of HLA class
II is increased in BM-MSCs [12, 17–19], adipose-derived stem
cells (ASCs) [20], and fMSCs after exposure to IFN-c [21]. In
our study, two clones of iPSC-MSCs at passages 7–9, fMSCs,
and BM-MSCs at passages 4–6 were exposed to recombinant
human IFN-c (200 ng/ml, Gibco, Invitrogen Corporation, CA)
and then subjected to analyses of HLA expression, costimula-
tory molecules, and transcription factors using flow cytometry,
Western blotting, immunocytochemistry, and quantitative
real-time PCR.
Flow Cytometry Analysis of HLA, Surface Marker, and
Costimulatory Molecule Expression
After 2 or 7 days of stimulation with IFN-c, the MSCs were
harvested and analyzed to determine their expression profile
of immunological molecules using specific monoclonal anti-
bodies against HLA class I (ABC), HLA class II (DR), CD80/B7-1,
CD 86/B7-2, CD40, CD3, CD105, CD90, CD34, CD45, CD14,
CD44, CD73, CD56 (BD Biosciences, San Diego, CA), and a BD
FACSCalibur flow cytometer (BD Biosciences, NJ) in accord-
ance with the manufacturer’s instructions. Isotype-matched
immunoglobulin (BD Biosciences) was used as the negative
control for each assay. The results represent five independent
experiments.
Western Blotting for HLA Expression
The MSCs were cultured for 2 and 7 days with or without
IFN-c for the examination of HLA class I and HLA class II.
Peripheral blood mononuclear cells (PBMCs) from healthy
human volunteers, which were obtained as described in our
previous study [22], were used as the positive control. Fur-
thermore, MSCs stimulated with IFN-c for 0 minute, 5
minutes, 30 minutes, 60 minutes, 6 hours, 2 days, and 7 days
were subjected to Western blot analyses to detect the levels
of p-STAT1 and total STAT1. The results represent four inde-
pendent experiments. The following antibodies were used:
human HLA-I and HLA-II (Abcam, Inc., Cambridge, MA),
phospho-STAT1 and STAT1 (Cell Signaling Technology, Beverly,
MA). The details are presented in Supporting Information
Methods.
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Immunocytochemistry for the Analysis of HLA
Expression
We then further assessed the expression of HLA-I and HLA-II
via immunocytochemistry. The different types of MSCs were
plated in 24-well plates with poly(L-lysine)-coated coverslips
and grown in culture medium with IFN-c. After 2 or 7 days,
the cells were fixed with 4% paraformaldehyde for 20
minutes, washed, permeated in 0.25% Triton X-100/phos-
phate-buffered saline (PBS), and blocked with 10% goat
serum. The cells were then incubated with mouse antibodies
against human HLA-I (Abcam, Inc.) and human HLA-II (Abcam,
Inc.) at 48C for 16 hours. After washing, the cells were incu-
bated with a goat anti-mouse Alexa 488-conjugated secondary
antibody (Molecular Probes, CA) for 2 hours at room temper-
ature. The cell nuclei were counterstained with 40,6-diami-
dino-2-phenylindole (DAPI, Sigma, MO). The results represent
four independent experiments. The sections were analyzed
under a fluorescent microscope.
RNA Extraction and Quantitative Real-Time PCR
The total RNA from the N1-iPSC-MSCs, iMR90-iPSC-MSCs,
fMSCs, and BM-MSCs cultured with IFN-c for 0, 2, and 7 days
was extracted using the TRIzol reagent (Invitrogen, CA). The
cDNA was synthesized using the M-MLV Reverse Transcriptase
kit (Promega, CA). The target transcripts of class II transactiva-
tor (CIITA), IFN-c receptor 1 (IFN-cR1), IFN-c R2, interferon
regulatory factor 1 (IRF-1), and regulatory factor X 5 (RFX5)
were quantified by real-time PCR with SYBR Premix Ex Taq
(TaKaRa, Japan) using the 18S rRNA as the internal control.
The primers used in the reverse transcription and quantitative
PCR assays are shown in Supporting Information Table S1.
The Treatment of p-STAT1 Inhibitor
In order to examine the role of p-STAT1 signaling pathway in the
expression of HLA-II, 100 lm fludarabine (Sigma) (p-STAT1 inhibi-
tor) was added into the medium of BM-MSCs for 1.5 days. More-
over, BM-MSCs were stimulated with IFN-c for 1.5 or 2 days. The
cells were harvested for Western blotting for p-STAT1, total STAT1,
and HLA-II, and quantitative PCR for CIITA and IRF-1.
Isolation of Human Dendritic Cells and HLA Expression
Assay
Dendritic cells (DCs) were isolated from adult healthy volun-
teers, and these cells were used as the positive controls for
the expression of HLA-I and HLA-II, which was analyzed via
flow cytometry analysis and immunocytochemistry. The details
are presented in Supporting Information Methods.
Immune Humanized Mice of Hind Limb Ischemia,
Laser Doppler Imaging, and Masson Trichrome
Staining
All procedures involving the immune humanized mice were
approved by the Committee on the Use of Live Animals in
Teaching and Research at The University of Hong Kong. Criti-
cal hind limb ischemia was established in NOD.Cg-Prkdc(Scid)
II2rg(tm1Wjl)/SzJ immunocompromised (NSG) mice (kind gifts
from Dr. Camie Chan, The University of Hong Kong). These
NSG mice lack mature T cells, B cells, or functional natural
killer cells, and are deficient in cytokine signaling, leading to
better engraftment of human hematopoietic cells [23].
Immune humanized mice were induced by intravenous injec-
tion of 3.0 3 106 PBMCs as previously described (abbreviated
as Hu-PBMC mice) [24]. Hind limb ischemia of above mice
was induced as our previous study [13]. Briefly, after anesthe-
sia with xylazine (20 mg/kg) and ketamine (100 mg/kg) by
intraperitoneal injection, the femoral artery of NSG mice was
excised from its proximal origin as a branch of the external
iliac artery to the distal point where it bifurcates into the
saphenous and popliteal arteries. After arterial ligation with 8-
0 suture, Hu-PBMC mice were randomized to receive follow-
ing treatments: (a) PBS (PBS group, n 5 10), (b) 3.0 3 106
BM-MSCs (BM-MSCs group, n 5 10), or (c) 3.0 3 106 N1-
iPSC-MSCs (iPSC-MSCs group, n 5 10). In order to examine
the MSCs engraftment post-transplantation, both injected
BM-MSCs and iPSC-MSCs were labeled with green fluorescent
protein (GFP). In each NSG mouse, a total of 3.0 3 106 cells
in 200 ll PBS or the same volume medium PBS was intra-
muscularly injected into four sites of the gracilis muscle at
the medial thigh of the ischemic hind limbs. Blood flow of
ischemic limbs was detected by laser Doppler imaging analysis
(Moor Instruments, Devon, U.K.) at Days 0, 7, 14, and 21 after
cell administration. At Day 21, muscle tissues of the ischemic
limbs were collected, formalin fixed, paraffin embedded, and
sectioned. Hematoxylin and eosin (HE) staining and Masson
trichrome staining were performed to assess the tissue dam-
age and fibrosis formation of ischemic limbs, respectively.
Immunostaining Assays of Cell Retention and
Inflammation
To detect the engraftment of injected cells post-transplantation,
muscle sections were stained with polyclonal rabbit anti-GFP
(Santa Crus, CA). The inflammation of ischemic hind limbs was
assessed by staining of CD45 (BD Pharmingen, San Diego, CA),
CD4 (Santa Cruz), and HLA-II (Abcam, Inc.), respectively. The pri-
mary antibodies were incubated at 48C overnight with a 1:100
dilution. After washed with PBS three times, the sections were
incubated with the secondary antibodies for 1 hour at room tem-
perature.The sections were incubated with biotin-conjugated sec-
ondary antibody (DakoCytomation, Glostrup, Denmark) and
visualized with diaminobenzidine. The nuclei were counterstained
by hematoxylin. For fluorescent immunostaining, the sections
were mounted with DAPI and the photographs were captured by
a deconvoluted fluorescentmicroscope.
Fluorescence-Activated Cell Sorting and Flow
Cytometry Analysis for Cell Retention and
Inflammation
To further study the survival rate of MSCs post-transplantation,
the ischemic limbs were digested and then the associated cells
were filtered. The surviving GFP1-MSCs were counted by FAC-
SAria II. For analysis of the inflammatory cell infiltration, associ-
ated cells were incubated with anti-CD45 (BD Biosciences) and
then subjected to flow cytometry on a BD FACSCalibur. The
data were analyzed by FlowJo software.
Statistical Analysis
The experimental data are expressed as the means 6 SEM.
The data with a Gaussian distribution were statistically ana-
lyzed using one-way analysis of variance. For multiple compar-
isons, the data with variance homogeneity were then
subjected to Tukey’s test, whereas the data with variance
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heterogeneity were subjected to Dunnett’s test. The compari-
sons between two groups were performed using an unpaired
Student’s t test. The Kruskal-Wallis rank sum test and the
Mann-Whitney U test were performed for two-group compari-
sons of data with an abnormal distribution. The statistical
analyses were performed using the SPSS 13.0 software (SPSS,
Inc., IL), and p < .05 was considered statistically significant.
RESULTS
Detection of the Expression of HLA Proteins in Human
iPSC-MSCs, fMSCs, and Adult BM-MSCs by Flow
Cytometry
Many studies have demonstrated that human MSCs derived
from adult tissues, such as BM-MSCs [12, 17–19], express
Figure 1. Flow cytometric detection of the expression profiles of HLA class I and II in MSCs in the absence and presence of IFN-c. (A):
The plots show BM-MSCs, fMSCs, N1-iPSC-MSCs, and iMR90-iPSC-MSCs with and without stimulation with IFN-c for 2 or 7 days. The N1-
iPSC-MSCs and iMR90-iPSC-MSCs exhibit low levels of HLA-I after incubation in the medium with 2 days (c, d) and low levels of HLA-II
after stimulation with IFN-c (g, h). The BM-MSCs exhibited markedly increased HLA-II expression 2 and 7 days after IFN-c addition (e, red
and blue lines). The fMSCs only exhibited a moderate increase in the HLA-II levels after 7 but not 2 days of stimulation with IFN-c (f, red
line). (B): The statistical analysis demonstrates lower levels of HLA-I in iPSC-MSCs compared with fMSCs and BM-MSCs. The HLA-I levels
significantly increased in all the MSCs after IFN-c addition. (C): The statistical analysis demonstrates the levels of HLA-II in MSCs. After 7
days of activation, the levels of HLA-II were highest in BM-MSCs, moderate in fMSCs, and lowest in N1-iPSC-MSCs and iMR90-iPSC-MSCs.
Five independent experiments were performed for each group (mean 6 SEM). *, p < .05; **, p < .01, and ***, p < .001, as determined
through one-way analysis of variance with post hoc analysis for the HLA-I levels in all the MSCs and the HLA-II levels after 7 days and
through the Kruskal-Wallis rank sum test followed by the Mann-Whitney U test for the two-group comparisons of the other parameters.
HLA-ABC, HLA-I; HLA-DR, HLA-II; ISO, isotype control; P2d, 2 days poststimulation; P7d, 7 days poststimulation. Abbreviations: BM, bone
marrow; fMSC, fetal mesenchymal stem cell; HLA, human leukocyte antigen; IFN-c, interferon-c; iPSC, induced pluripotent stem cell.
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HLA-class I but only express HLA-class II after stimulation with
IFN-c. Similarly, we found that both BM-MSCs and fMSCs
express high levels (more than 90%) of HLA class I with or
without treatment with IFN-c for 2 and even 7 days (Fig. 1A,
1B). In contrast, the levels of HLA-I observed in two clones of
N1-iPSC-MSCs and iMR90-iPSC-MSCs were lower compared to
those observed in fMSCs and BM-MSCs after 2 days of treat-
ment with only medium (p < .01 or p < .001). Moreover, the
N1-iPSC-MSCs and iMR90-iPSC-MSCs expressed higher levels
of HLA-I after 2 and 7 days of stimulation and after 7 days
without stimulation compared to the levels observed after 2
days without stimulation with IFN-c (p < .01 or p < .001)
(Fig. 1A, 1B). In addition, the levels of HLA-I in the N1-iPSC-
MSCs were lower than those observed in fMSCs and BM-
MSCs after 2 days of IFN-c stimulation (p < .05). The iMR90-
iPSC-MSCs expressed lower levels of HLA-I after 7 days in the
absence of stimulation compared with the levels obtained
after stimulation (p < .05).
The HLA class II molecules were not expressed on the two
clones of iPSC-MSCs, fMSCs, and BM-MSCs after 2 days in the
absence of IFN-c stimulation (Fig. 1A, 1C). Two days after IFN-
c activation, the expression of HLA class II molecules
increased significantly to 86% in the BM-MSCs (p < .01), and
lower increases were observed in the fMSCs, N1-iPSC-MSCs,
and iMR90-iPSC-MSCs (p < .05). The HLA class II molecules
were more highly expressed in BM-MSCs compared to the
Figure 2. Immunoblotting of HLA class I and II proteins in MSCs after treatment with and without IFN-c. (A): Western blotting of HLA-I
and HLA-II proteins in different MSCs after 2 and 7 days in the presence or absence of IFN-c. Human PBMCs were used as the positive
control for the expression of HLA-I and HLA-II. HLA-I was expressed in all the MSCs, and no differences were observed between the dif-
ferent cells. After 2 and 7 days of IFN-c stimulation, HLA-II was expressed at high levels in BM-MSCs, and medium levels of HLA-II were
observed in fMSCs after 7 days of stimulation, whereas HLA-II expression was not detected in iPSC-MSCs. (B, C): Densitometric scanning
of the HLA-I and HLA-II proteins detected by Western blotting. The protein levels are expressed as relative values compared with the
levels observed BM-MSCs after 7 days of stimulation with IFN-c. The data were analyzed using an unpaired Student’s t test for compari-
sons between two groups. **, p < .01. P2d, 2 days poststimulation; P7d, 7 days poststimulation. Abbreviations: BM, bone marrow;
fMSC, fetal mesenchymal stem cell; GAPDH, glyceraldehyde phosphate dehydrogenase; HLA, human leukocyte antigen; IFN-c, interferon-
c; iPSC, induced pluripotent stem cell; nd, no detection; PBMC, peripheral blood mononuclear cell.
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other three types of MSCs after 7 days in the absence of
stimulation with IFN-c. Moreover, 7 days after IFN-c treat-
ment, the expression of HLA class II was higher in the BM-
MSCs (98%) compared with the fMSCs (58%), N1-iPSC-MSCs
(19%), and iMR90-iPSC-MSCs (23%) and higher in fMSCs com-
pared to the two clones of iPSC-MSCs (all p < .001). In addi-
tion, a higher expression level of HLA class II was observed in
the BM-MSCs 7 days after IFN-c treatment compared with
those observed after 2 days of stimulation with IFN-c and 7
days in the absence of stimulation (all p < .001). We
observed that the expression of HLA-II molecules in iPSC-
MSCs, fMSCs, and BM-MSCs decreased successively depending
on the increase in the stemness of the original source of the
MSCs. We justified the results using three different passages
of each MSCs, and no significant differences were observed
between the cells from different passages.
Both the interaction between the peptide-MHC and the T-
cell receptor and the costimulation provided by the interac-
tion of a group of complementary molecules are required for
T-cell activation. Previous studies showed that BM-MSCs [2,
11] and ASCs [20] do not express the costimulatory molecules
CD80/B7-1, CD 86/B7-2, and CD40 even after stimulation with
IFN-c. In this study, we used flow cytometry to show that
CD80, CD86, and CD40 are not expressed in all the tested
MSCs after 2 or 7 days in the presence or absence of IFN-c
(Supporting Information Fig. S1).
We further examined the classic surface proteins of MSCs
in the three different MSC types using flow cytometry. BM-
MSCs, fMSCs, and two clones of iPSC-MSCs were defined as
CD452, CD142, CD342, CD32, CD562, CD441, CD1051,
CD901, and CD731 with and without the stimulation of IFN-
c. There was no difference for the levels of the surface pro-
teins between three types of MSCs, and for each type of
MSCs with and without the stimulation (Supporting Informa-
tion Fig. S2).
Detection of the Expression of HLA Proteins in Human
iPSC-MSCs, fMSCs, and BM-MSCs Through
Immunoblotting
All the MSCs derived from the adult BM, fetus, and two
clones of iPSCs expressed HLA-class I molecules after 2 or 7
days in the presence or absence of IFN-c (Fig. 2A). There was
no significant difference in the HLA-I levels between the
groups (Fig. 2A, 2B). As in a previous study [2, 17, 25], the
BM-MSCs did not express HLA-II after 2 or 7 days in the
absence of stimulation (Fig. 2A, 2C). Similarly, the fMSCs, N1-
iPSC-MSCs, and iMR90-iPSC-MSCs did not express HLA-II mol-
ecules after culture in medium for 2 or 7 days. However,
there was a marked increase in the HLA-II levels observed in
BM-MSCs after 2 and 7 days of IFN-c stimulation. Moreover,
intermediate expression levels of HLA-II were observed in
fMSCs after 7 but not 2 days of stimulation with IFN-c, and
this increased level was significantly lower than that observed
in the BM-MSCs (p < .01). We did not observe any HLA-II
expression in the two different clones of N1-iPSC-MSCs and
iMR90-iPSC-MSCs after activation with IFN-c. The HLA-II levels
observed in MSCs after activation exhibited progressive reduc-
tion with an increase in the stemness of the original tissues
or cells from which the MSCs were derived. The positive con-
trol, which consisted of PBMCs from healthy humans,
expressed both HLA class I and HLA class II molecules after 2
and 7 days of culture.
Detection of the Expression of HLA Proteins in Human
iPSC-MSCs, fMSCs, and BM-MSCs Through
Immunofluorescence
To further confirm the expression of HLA-class I and HLA-class
II molecules in MSCs, we examined their location through
immunofluorescence. Few reports have described the detec-
tion of HLA expression in MSCs by immunocytochemistry.
First, we investigated the expression of HLA molecules in
human DCs (Supporting Information Fig. S3). As in a previous
report [26], the intracellular HLA (MHC)-I staining in immature
DCs exhibited a fine punctate or a silver-stained nearly reticu-
lar pattern reminiscent of the endoplasmic reticulum (ER).
Some MHC I molecules also accumulated in the perinuclear
region, which may correspond to cisternal Golgi elements
(Supporting Information Fig. S3A). In mature DCs, most of the
HLA-I was found in the plasma membrane (Supporting Infor-
mation Fig. S3B). As in a previous study, the HLA (MHC)-II
proteins congregated to large granules with characteristics of
lysosomal structures in immature DCs and appeared at the
plasma membrane in mature DCs (Supporting Information Fig.
S3C, S3D).
The HLA-I proteins exhibited a similar pattern with fine
punctates in the cytoplasm and conglomeration outside the
nucleus in BM-MSCs, fMSCs, and iPSC-MSCs (Fig. 3A-a). The
HLA-I staining was weak in both N1-iPSC-MSCs and iMR90-
iPSC-MSCs but strong in BM-MSCs and fMSCs cultured in the
medium for 2 days. Most of the HLA-I proteins remained in
intracellular locations but not at the membrane in all types of
MSCs after IFN-c administration. Interestingly, we observed
that a portion of the HLA-I molecules in BM-MSCs and partic-
ularly fMSCs were recruited to the end of the polar bodies
and formed a fissional pattern between adjacent cells 7 days
after the addition of IFN-c (Fig. 3A-b).
No positive staining for HLA-II was observed in any of the
MSCs in the absence of IFN-c stimulation 2 or 7 days. We
observed a similar intracellular granular pattern of HLA-II
staining in a small number of BM-MSCs after 2 days of IFN-c
stimulation (Fig. 3B). It was interesting that some of the HLA-
II staining resembled a bead with a little eye in the center
(Fig. 3B-a). No positive staining for HLA-II was found in fMSCs,
N1-iPSC-MSCs, and iMR90-iPSC-MSCs after IFN-c stimulation
for 2 days. Seven days after IFN-c addition, almost all BM-
MSCs expressed positive and strong HLA-II staining. Further-
more, some of the fMSCs also exhibited HLA-II-positive stain-
ing. Only a few of the N1-iPSC-MSCs and iMR90-iPSC-MSCs
expressed HLA-II proteins. More importantly, we observed
HLA-II expression only at the surface of a few BM-MSCs, but
no surface expression was detected in the fMSCs and iPSC-
MSCs (Fig. 3B-b), which indicates their potential ability to fully
present exogenous antigens. These data suggest that HLA-II
molecules are actively synthesized in a time-dependent man-
ner after IFN-c stimulation in BM-MSCs and that some of the
proteins were delivered to the cell surface. In contrast, the
iPSC-MSCs synthesized few HLA-II molecules even after long-
term stimulation with IFN-c for 7 days.
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Figure 3. Immunofluorescence of HLA class I and II proteins in MSCs with and without IFN-c treatment. (A): HLA-I expression. The
HLA-I proteins were stained as fine punctates in the cytoplasm and exhibited conglomeration outside of the nucleus (a). Some of the
HLA-I proteins were recruited to the end of the polar bodies and formed a fissional pattern with the adjacent cells (b, white arrow-
head). Strong HLA-I expression was detected in all the MSCs under the different conditions with the exception of N1-iPSC-MSCs and
iMR90-iPSC-MSCs after 2 days of culturing in the absence of IFN-c. (B): HLA-II expression. The HLA-II staining was observed as intracellu-
lar granules (white arrows) and sometimes presented as beads with little eyes in the center, following a nearly lysosomal pattern (a).
A few of the BM-MSCs exhibited HLA-II-positive staining at the cell surface after 7 days of IFN-c stimulation (b). HLA-II-positive staining
was found in BM-MSCs but not fMSCs and iPSC-MSCs 2 days after IFN-c stimulation. Seven days after IFN-c stimulation, the highest
HLA-II expression was found in the BM-MSCs, whereas moderate HLA-II expression was detected in the fMSCs, and the lowest HLA-II
expression was found in the iPSC-MSCs. Aa, Ba, Bb, Representative photographs of BM-MSCs 7 days after IFN-c addition. Ab, Represen-
tative photograph of fMSCs 7 days after IFN-c addition. The green staining represents the HLA molecules. The blue staining shows the
cell nuclei, which were counterstained with 40,6-diamidino-2-phenylindole. Scale bar is 10 lm in A-a,b and B-a,b, and 25 lm for the rest
pictures. P2d, 2 days poststimulation; P7d, 7 days poststimulation. Abbreviations: BM, bone marrow; fMSC, fetal mesenchymal stem
cell; IFN-c, interferon-c; iPSC, induced pluripotent stem cell.
Phosphorylation of STAT-1 and Activation of IRF-1 and
CIITA Among BM-MSCs, fMSCs, and iPSC-MSCs
Upon the binding of IFN-c to its cognate receptor, STAT1
phosphorylation is activated in APCs and other cell types.
Phospho-STAT1 and IRF-1 drive CIITA, which is obligatory for
the transcription of MHC-II molecules. To further examine the
possible mechanism underlying the differential activation of
HLA-II in iPSC-MSCs, fMSCs, and BM-MSCs, we investigated
Figure 4.
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the STAT1 signaling pathway and the genes involved in the
induction of MHC-II molecules. The phosphorylation of STAT1
at a tyrosine residue markedly increased starting 5 minutes
and maintained the maximum level up to 60 minutes after
the addition of IFN-c and was decreased after 6 hours of IFN-
c stimulation in all the BM-MSCs, fMSCs, N1-iPSC-MSCs, and
iMR90-iPSC-MSCs (Fig. 4A). After a decline from the maxi-
mum, BM-MSCs maintained a certain level of p-STAT1 from 6
hours up to 7 days after IFN-c addition (Fig. 4A-a). However,
the fMSCs only maintained this level of p-STAT1 up to 2 days,
then returned to almost the level of untreated controls at 7
days (Fig. 4A-b). Moreover, the N1-iPSC-MSCs and iMR90-
iPSC-MSCs maintained some p-STAT1 expression up to 6 hours
after IFN-c addition, but this level was decreased to the basal
level after 2 and 7 days (Fig. 4A-c, 4A-d). The activation of p-
STAT1 was significantly higher in BM-MSCs (100%) and fMSCs
(98%) compared to N1-iPSC-MSCs and iMR90-iPSC-MSCs with
an increase of only 24%–34% after 2 days of IFN-c stimulation
(Fig. 4A-f, all p < .001). There was no difference in the p-
STAT1 level between BM-MSCs and fMSCs after 2 days of
stimulation. After 7 days of IFN-c stimulation, the BM-MSCs
(105%) exhibited a higher level of p-STAT1 compared with the
fMSCs (38%, p < .001) and the two different clones of iPSC-
MSCs (10%–12%), and the fMSCs presented a higher level
compared to the iPSC-MSCs (p < .05). Similarly to the expres-
sion of HLA-II in the MSCs derived from different origins,
these data suggest a similar trend that p-STAT1 levels under-
went a decline in sequence from BM-MSCs to fMSCs and to
iPSC-MSCs. The different levels of p-STAT1 observed after acti-
vation may provide an explanation for the differential expres-
sion of HLA-II in these MSCs. The low level of p-STAT1 may
predicate the low level of HLA-II molecules observed in iPSC-
MSCs. The total STAT1 levels in BM-MSCs, fMSCs, N1-iPSC-
MSCs, and iMR90-iPSC-MSCs remained at the basal levels
from 0 to 6 hours and were increased after 2 and 7 days of
treatment with IFN-c.
We further investigated the mRNA expression levels of
IFN-c R1, IFN-c R2, and the transcription factors CIITA, IRF-1,
and RFX5, which may be involved in the activation of MHC-II
molecules, using quantitative RT-PCR (Fig. 4B). Under the
basal conditions, the BM-MSCs exhibited high levels of CIITA
compared to the fMSCs, N1-iPSC-MSCs, and iMR90-iPSC-MSCs
(p < .001) and presented high levels of IRF-1 compared to
N1-iPSC-MSCs and iMR90-iPSC-MSCs (p < .01). In addition,
the fMSCs had high levels of CIITA and IRF-1 compared to the
N1-iPSC-MSCs and iMR90-iPSC-MSCs (all p < .001) (Fig. 4B-a).
IFN-c markedly enhanced the levels of CIITA in BM-MSCs by
more than 200-fold and in fMSCs by 15- and 117-fold after 2
and 7 days of stimulation, respectively (all p < .001). The lev-
els of CIITA in iPSC-MSCs were increased but remained low
after the addition of IFN-c. The BM-MSCs expressed higher
levels of CIITA and IRF-1 compared to the fMSCs and the two
clones of iPSC-MSCs after 2 and 7 days of stimulation (all p <
.001). Furthermore, the fMSCs expressed higher levels of CIITA
and IRF-1 compared to N1-iPSC-MSCs and iMR90-iPSC-MSCs
after 2 and 7 days of stimulation (all p < .001). Similarly to
the p-STAT1 expression results, the expression of CIITA and
IRF-1 exhibited a gradual decrease from BM-MSCs to fMSCs
to iPSC-MSCs after activation. We did not observe any signifi-
cant difference in the expression of IFN-c R1, IFN-c R2, and
RFX5 between the different types of MSCs after IFN-c stimula-
tion. Our data suggest that the low levels of p-STAT1 and
CIITA may be responsible for the low levels of MHC-II found
in iPSC-MSCs.
Furthermore, we investigated the role of p-STAT1 signaling
pathway in the expression of HLA-II using fludarabine to block
the phosphorylation of STAT1 and the downstreams (Fig. 4C).
We observed that fludarabine had clear toxicity to MSCs after
the treatment of more than 1.5 days even with low concen-
tration of 10 lm. We finally confirmed 100 lm fludarabine of
1.5-day-treatment for our study as both more safety to the
cells and the bigger effects to decrease the levels of p-STAT1.
We found that fludarabine clearly but not completely
decreased the phosphorylation of STAT1 to the baseline in
BM-MSCs after the stimulation of IFN-c for 1.5 days (p <
.001, Fig. 4C-a, 4C-b). However, even current treatment of flu-
darabine completely blocked the expression of HLA-II in BM-
MSCs after 1.5 days-IFN-c stimulation, and still with little
expression at 2 days-IFN-c stimulation. Furthermore, fludara-
bine dramatically reduced the high gene levels of CIITA
Figure 4. Activation of STAT1 and the expression of transcription factors involved in the synthesis of HLA-II protein in MSCs with and
without IFN-c treatment. (A): The activation of STAT1 at different time points after IFN-c stimulation was detected through immunoblot-
ting. (a–d) The phosphorylation of STAT1 rapidly and markedly increased starting 5 minutes and maintained the maximum level up to
60 minutes after the addition of IFN-c, and declined 6 hours after IFN-c addition in all four types of MSCs. A certain level of p-STAT1
was maintained in BM-MSCs 2 and 7 days after IFN-c addition and in fMSCs 2 but not 7 days after IFN-c addition, whereas the iPSC-
MSCs presented a return to the basal p-STAT1 levels within 2 days after IFN-c addition. (e, f) The iPSC-MSCs exhibited lower levels of p-
STAT1 after 2 and 7 days of treatment compared with BM-MSCs and fMSCs. In addition, the BM-MSCs presented a higher level of p-
STAT1 compared to fMSCs, and the fMSCs exhibited a higher level compared with the iPSC-MSCs. (f) Densitometric scanning of the p-
STAT1 protein level detected by Western blotting. The protein levels are expressed as relative values compared with the levels observed
in BM-MSCs after 2 days of stimulation with IFN-c. (B): The expression levels of CIITA and IRF-1 in MSCs after treatment with IFN-c
were detected through qRT-PCR. (a) IFN-c markedly enhanced the levels of CIITA in BM-MSCs and in fMSCs but not in iPSC-MSCs. The
levels of CIITA in iPSC-MSCs were lower compared to those observed BM-MSCs and fMSCs 2 and 7 days after IFN-c addition. The fMSCs
presented lower levels of CIITA compared to BM-MSCs after 2 and 7 days of stimulation. (b) IFN-c enhanced the levels of IRF-1 in BM-
MSCs and in fMSCs but not in iPSC-MSCs. (C): The effects of fludarabine on BM-MSCs with the treatment of IFN-c. (a) Western blotting
for p-STAT1, STAT1, and HLA-II with the treatment of both of fludarabine and IFN-c. (b) Densitometric scanning of the p-STAT1 and HLA-
II protein levels detected by Western blotting. The protein levels are expressed as relative values compared with the levels observed in
BM-MSCs after 1.5 days of stimulation with IFN-c. (c) CIITA and IRF-1 gene levels. *, p < .05; **, p < .01; and ***, p < .001, as deter-
mined through one-way analysis of variance with post hoc analysis for the data with a normal distribution or through the Kruskal-Wallis
rank sum test followed by the Mann-Whitney U test for two-group comparisons of data with an abnormal distribution. P2d, 2 days post-
stimulation; P7d, 7 days poststimulation. Abbreviations: BM, bone marrow; CIITA, class II transactivator; fMSC, fetal mesenchymal stem
cell; GAPDH, glyceraldehyde phosphate dehydrogenase; HLA, human leukocyte antigen; IFN-c, interferon-c; iPSC, induced pluripotent
stem cell; IRF-1, interferon regulatory factor 1; nd, not detection; STAT1, the signal transducer and activator of transcription 1.
Sun, Zhang, Li et al. 9
www.StemCells.com VC 2015 The Authors. STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
Figure 5. Examination of cell retention and inflammation postcell transplantation. (A): Cell retention was detected by staining of GFP in
BM-MSCs group (a, b) and iPSC-MSCs group (c, d) in the ischemia limbs on Day 7 and Day 21, respectively. Arrows showed engrafted BM-
MSCs and iPSC-MSCs in the ischemic limb with GFP positive. The engrafted cell was calculated on Day 7 and Day 21 from BM-MSCs and
iPSC-MSCs group (n 5 6, **, p < .01 at different time points). (B): Representative flow cytometric plots show surviving GFP1-MSCs counted
by fluorescence activated cell sorting in BM-MSCs (a, b) and iPSC-MSCs group (c, d). Gate A shows all the associated cells from the ischemia
limbs. Gate E shows the GFP1-MSCs out of gate A. The survival rate of MSCs at different time points were analyzed (e) (n 5 5, **, p < .01
at different time points). (C): Representative photos of immunofluorescence staining showing CD45- (a–c) and CD4- (e–g) positive cells in the
ischemia limbs at Day 21 among different groups, respectively. Arrows showed CD45- and CD4-positive cells in the ischemia limbs. The per-
centage of CD45- and CD4-positive cells in the ischemia limbs among different groups was analyzed at Day 21 (d, h) (n 5 6, **, p < .01).
Quantitative measurement of CD45 (d) and CD4 (h) was expressed as percent of positive staining versus total per myocardium area. (D):
CD45-positive cells in the ischemia limbs at Day 21 among different groups were analyzed by flow cytometry. (E): The expression of MHC-II
in MSCs in the ischemia limbs after transplantation at 7 days and 21 days was detected among in BM-MSCs (a–f) and iPSC-MSCs group (h–
m). The percentage of MHC-II positive cells in BM-MSCs was calculated at 7 days and 21 days, respectively, (n 5 5, **, p < .01 at different
time points). The scale bars represent 50 lm. Abbreviations: BM, bone marrow; GFP, green fluorescent protein; iPSC, induced pluripotent
stem cell; MSC, mesenchymal stem cell; PBS, phosphate-buffered saline.
(p < .001, Fig. 4C-c) and had partly effects to decrease of
IRF-1 expression (p < .05). The data further confirmed that
p-STAT1 and CIITA genes were involved in the induction of
HLA-II in MSCs after IFN-c stimulation.
Examination of Cell Retention and Inflammation
Post-MSC Transplantation in ischemic Limbs of
Immune Humanized NOD Scid Gamma Mice
To further examine the expression of HLA-II between BM-
MSCs and iPSC-MSCs and their immune privilege under the
state of diseases, we transplanted them into the hind limb
ischemia model of hu-PBMNC mice. The cell retention of BM-
MSCs and iPSC-MSCs post-transplantation was examined at
Day 7 and Day 21, respectively. At Day 7, GFP staining
revealed that both BM-MSCs and iPSC-MSCs were detected.
Moreover, the number of GFP-positive cells in iPSC-MSCs
group was much higher than BM-MSCs group (297 6 8.3/
mm2 vs. 178 6 9/mm2, Fig. 5A-a, 5A-b, 5A-e; p < .01). At
Day 21, the number of GFP-positive cells retained in the
ischemic limbs was markedly reduced in both iPSC-MSCs
group and BM-MSCs group compared with Day 7. Notably,
GFP-positive cells in iPSC-MSCs group were still much higher
than BM-MSCs group (82 6 5.4/mm2 vs. 35 6 3/mm2, Fig.
5A-c–5A-e, p < .01). To further quantify cell survival, ischemic
limbs were digested at 7 days and 21 days after transplanta-
tion, respectively. As shown in Figure 5B, compared with BM-
MSCs group, more GFP1 cells were indentified in iPSC-MSCs
group (Fig. 5B-a–5B-d). The cell survival rate was calculated by
the surviving cells to the total transplanted cells. At 7 days,
the cells survival rate was much higher in iPSC-MSCs group
than BM-MSCs group (7.32% 6 0.4% vs. 4% 6 0.3%, Fig. 5B-e;
p < .01). However, at 21 days, the survival GFP1 cells were
dramatically decreased in ischemic limbs compared with
7 days. Notably, the survival rate of iPSC-MSCs was still much
higher than BM-MSCs (2.88% 6 0.3% vs. 0.94% 6 0.1%,
Fig. 5B-e; p < .01).
The inflammation in the ischemic limbs was examined by
immunofluorescence staining of CD45 and CD4, respectively.
As shown in Figure 5C, the percentage of CD45- and CD4-
positive cells in BM-MSCs group (Fig. 5C-b, 5C-d, 5C-f, 5C-h)
and iPSC-MSCs group (Fig. 5C-c, 5C-d, 5C-g, 5C-h) was signifi-
cantly decreased compared with PBS group (Fig. 5C-a, 5C-d,
Figure 5. Continued
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5C-e, 5C-h; p < .01). Notably, the percentage of both CD45-
and CD4-positive cells in iPSC-MSCs group was much lower
than in BM-MSCs group (p < .01). The inflammatory cell infil-
tration was also examined by flow cytometry. As shown in
Figure 5D, CD45 positive cells were significantly reduced in
iPSC-MSCs group compared with BM-MSCs group at 21 days.
Our results demonstrated that iPSC-MSCs have a stronger
immune privilege than BM-MSCs.
Moreover, to further investigate the expression of HLA-II
of MSCs after transplantation, GFP and HLA-II co-staining
were performed. As shown in Figure 5E, the expression of
HLA-II in BM-MSCs in the ischemic limbs was detected at 7
days and 21 days after injection in BM-MSCs group (Fig. 5E-a–
5E-f). Moreover, the percentage of MSCs expressing HLA-II
was greatly increased at 21 days compared with 7 days
(33.4% 6 9% vs. 18% 6 5.9%, Fig. 5E-g; p < .01). Interest-
ingly, no HLA-II was detected in iPSC-MSCs group. These
results further confirmed that iPSC-MSCs have a stronger
immune privilege than BM-MSCs (Fig. 5E-h–5E-m).
Transplantation of BM-MSCs and iPSC-MSCs Achieved
Differential Improvement of Blood Flow in ischemic
Limbs of Immune Humanized NOD Scid Gamma Mice
We next examined the different therapeutic effects of BM-
MSCs and iPSC-MSCs on ischemic limbs. As shown in Figure
6A-a, 6A-b, compared with the nonischemic limbs, the blood
Figure 6. Transplantation of BM-MSCs and iPSC-MSCs in improvement of blood flow in ischemic limbs. (A): Representative photos
showing the laser Doppler scanning at Day 0, Day 7, Day14, and Day 21 of ischemic limbs among the different groups (a). (b) The blood
flow from different groups was analyzed. Compared with PBS group, there was a gradual improvement of blood flow in BM-MSCs and
iPSC-MSCs group (n 5 6, *,p < .01 vs. PBS group at different time points). Moreover, there was also a significant difference between
BM-MSCs and iPSC-MSCs group (n 5 6, #,p < .01 vs. BM-MSCs group at different time points). (B): Representative photos of HE staining
showing the muscle degeneration among different groups. Representative photos of Masson trichrome staining showing interstitial fibro-
sis among different groups. HE staining demonstrated that the muscle degeneration of ischemic limbs was obviously protected in the
BM-MSCs and iPSC-MSCs groups. Masson trichrome staining showed that fibrosis was remarkably attenuated in the BM-MSCs and iPSC-
MSCs groups. The scale bars represent 200 lm. Abbreviations: BM, bone marrow; iPSC, induced pluripotent stem cell; MSC, mesenchy-
mal stem cell; PBS, phosphate-buffered saline.
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flow of the ischemic limbs was dramatically reduced at Day 0,
indicating that the hind limb ischemia model was successfully
established. From Day 7 on, the blood flow in BM-MSCs and
iPSC-MSCs groups was gradually increased compared with PBS
group (Fig. 6A-a, 6A-b; p < .01). At Day 21, compared with
the PBS group (18% 6 3.6%), the blood flow in BM-MSCs
group and iPSC-MSCs group was greatly increased to 44.7% 6
2.3% and 60.3% 6 3%, respectively (Fig. 6A-a, 6A-b; all
p < .01). Notably, there was a significant difference between
BM-MSCs group and iPSC-MSCs group (Fig. 6A-a, 6A-b;
p < .01), suggesting iPSC-MSCs are superior to BM-MSCs in
improvement of blood flow in a hind limb ischemia model of
NSG mouse. HE and Masson trichrome staining demonstrated
massive muscle degeneration and interstitial fibrosis formation
in PBS group (Fig. 6B-b, 6B-f) compared with control group
(Fig. 6B-a, 6B-e). In contrast, the muscle degeneration and
interstitial fibrosis formation were remarkably reduced in BM-
MSCs group (Fig. 6B-c, 6B-g) and iPSC-MSCs group (Fig. 6B-d,
6B-h). Moreover, less muscle degeneration and fibrosis were
observed in iPSC-MSCs group compared with BM-MSCs group.
DISCUSSION
In this study, we identified that human iPSC-MSCs did not
express HLA-I and costimulatory molecules, and expressed
very low levels of HLA-I molecules even with the treatment of
IFN-c. The levels of HLA-II molecules and the following signal-
ing pathway of p-STAT1 and genes of IRF-1, CIITA exhibited a
successive decrease in BM-MSCs, fMSCs, and iPSC-MSCs after
IFN-c stimulation. Moreover, human iPSC-MSCs exerted more
cell retention, less inflammation, no HLA-II expression, and a
better therapeutic efficacy compared to BM-MSCs in a model
of limb ischemia of immune humanized NSG mice. The lower
levels of HLA-II molecules and the following signaling proteins
and genes observed in human iPSC-MSCs but not BM-MSCs
after IFN-c treatment indicate that these cells may have more
potential clinical implications with a lower risk of rejection in
allogenic transplantation.
Previous studies have shown that adult MSCs are positive
for MHC class I and negative for MHC class II [12, 25]. The
addition of IFN-c for 2 or 3 days induces most human adult
BM-MSCs cells to express HLA-II [17–19, 25, 27]. Moreover,
another type of adult MSCs, namely human ASCs, has been
reported to express high levels of HLA-I but not HLA-II and
express high levels of HLA-II after IFN-c stimulation [20]. Fur-
thermore, approximately 100% HLA-I and 34% HLA-II mole-
cules are induced by IFN-c treatment in epiphysis-derived
MSCs [28]. In addition to adult MSCs, human fetal MSCs have
been reported to express HLA-I but not HLA-II [21, 29]. Stimu-
lation with IFN-c for 2 days initiates the intracellular synthesis
of HLA-II, but 7 days of exposure are required for cell surface
expression [21]. Our data on the expression of HLA-I and HLA-
II in BM-MSCs are consistent with the findings reported by
previous studies [12, 17–19]. We demonstrated that IFN-c
induces a high expression of HLA-I molecules in human BM-
MSCs, iPSC-MSCs, and fMSCs. No expression of HLA-II was
observed in all the tested types of MSCs in the absence of
IFN-c. However, after IFN-c stimulation, HLA-II molecules were
expressed at a high level in BM-MSCs, an intermediate level
in fMSCs, and a minimal level in iPSC-MSCs. More impor-
tantly, we confirmed these results using three different tech-
niques, namely flow cytometry, immunoblotting, and
immunofluorescence, and two different clones of iPSC-MSCs.
To the best of our knowledge, this report provides the first
detailed demonstration of the expression of HLA proteins in
human pluripotent stem cell-derived MSCs. It is interesting
that level of HLA-II activated in MSCs derived from fetuses
was between the high level observed in the adult MSCs from
the BM and the low level observed in MSCs derived from
iPSCs. This finding indicates that the HLA-II pattern in MSCs in
response to IFN-c exhibits a progressive reduction depending
on the enhancement of stemness of the original tissues
or cells.
We further identified the possible mechanisms underlying
the low expression of HLA-II in iPSC-MSCs. The MHC-II antigen
is constitutively expressed on professional APCs and can be
induced by IFN-c in other cell types, such as fibroblasts, epi-
thelial cells, and even BM-MSCs [18, 30, 31]. Upon the bind-
ing of IFN-c to its cognate receptor, IFN-cR1 and IFN-cR2,
STAT1 is activated to yield p-STAT1 [32]. Transcription factors,
including p-STAT1 and IRF-1, bind to their own enhancer
sequences in the IFN-c activation sequence element and drive
the transcription of CIITA, which is obligatory for the tran-
scription of the MHC-II gene [18, 33, 34]. In this study, simi-
larly to the trend of HLA-II expression described in the
different types of MSCs, the expression of p-STAT1, CIITA, and
IRF-1 progressively decreased from BM-MSCs to fMSCs to
iPSC-MSCs after IFN-c treatment. More importantly, very low
levels of p-STAT1, CIITA, and IRF-1 gene expression were
observed in iPSC-MSCs, which may result in the low induction
of the MHC-II molecule observed in these cells. Moreover, p-
STAT1 antagonist almost completely blocked the production of
HLA-II protein and CIITA gene levels in BM-MSCs with the
stimulation of IFN-c even still with some phosphorylation of
STAT1. p-STAT1 antagonist only partly affected the IRF-1 gene
levels, which may be because IRF-1 is also involved in the
production of MHC-I protein or the other proteins [18]. Unlike
a previous report [18], we observed no difference in the
expression levels of the IFN-cR1 and IFN-cR2 genes even in
BM-MSCs after IFN-c stimulation. This discrepancy may be
due to the different cell origins or different culture conditions.
The possible pathways involved in HLA-II expression in iPSC-
MSCs are summarized in Figure 7. In human iPSC-MSCs, IFN-
cR1 and IFN-cR2 are maintained at low levels after stimula-
tion with IFN-c. The phosphorylation of STAT1 remains low
and thus results in low levels of p-STAT1 homodimerization.
Together with low IRF-1, the few p-STAT1 dimers bind to the
promoter regions of CIITA to result in low levels of transcrip-
tion. The resulting low levels of CIITA protein are not suffi-
cient to induce the expression of HLA-II molecules. In
addition, low levels of p-STAT1 may result in low expression
levels of the IRF-1 and CIITA genes.
Consistent with previous reports about the negative
expression of costimulatory molecules in BM-MSCs [12], ASCs
[20], and MSCs derived from the umbilical cord [29], we dem-
onstrated that iPSC-MSCs, fMSCs, and BM-MSCs do not
express costimulatory molecules regardless of the presence of
IFN-c. In general, cells that express MHC molecules can either
stimulate T cells directly if they possess the appropriate costi-
mulatory molecules [35] or activate T cells through an indirect
pathway through cross presentation of their MHC antigens by
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professional APCs. The cells will be rejected by the immune
system unless suppressive or tolerogenic mechanisms are
used. The low immunogenicity and immunosuppressive nature
of MSCs are of clinical relevance to achieve low transplanta-
tion rejection in allogenic transplantation. Human or rat MSCs
induce a weak immune response in the rat striatum after
allo- or xeno-transplantation, and these animals express very
few DCs and Tab- cells and no Tcd-lymphocytes [36]. The
transplantation of allogeneic MSCs into baboons has been
found to be well tolerated [3, 4].
We further used the immune humanized NOD Scid
gamma mice to examine the effects of iPSC-MSCs after trans-
plantation. We induced a hind limb ischemia model and found
that more iPSC-MSCs remained in the injected muscle com-
pared to BM-MSCs after the transplantation. There was much
lower inflammation for iPSC-MSCs group compared with PBS
group and BM-MSCs group. Moreover, the expression of HLA-
II in MSCs was detected in BM-MSCs group but not in iPSC-
MSCs group at 7 and 21 days after transplantation. iPSC-MSCs
significantly improved the blood flow in above mice and supe-
rior to BM-MSCs. These data suggest that allogenic transplan-
tation of iPSC-MSCs to humanized mice had the potential to
be tolerated and exhibited good effects for the ischemia.
There is some evidence that BM-MSCs are immunogenic and
can induce T-cell responses through their MHC-I and MHC-II
molecules or even CD80 in the presence of IFN-c stimulation
[37–39]. In our study, we found the upregulation of both
MHC-II expression and the involved pathways, that is, p-
STAT1, IRF-1, and CIITA, in BM-MSCs but not in iPSC-MSCs
after IFN-c stimulation. It suggests that human iPSC-MSCs
have greater advantages to escape immune rejection in allo-
genic transplantation. Even that allogenic BM-MSCs are cur-
rently used for the patients in clinical trials such as GvHD [6,
7], the lower immunogenicity of iPSC-MSCs indicates a greater
application in allogenic transplantation for patients. More
importantly, it also provide a promising projection that iPSC-
MSCs have the possibility to be produced as common biologi-
cals and are easier to use with a low level of transplantation
rejection in allogenic transplantation.
There are some controversial findings regarding the role
of MHC molecules in MSCs. Some papers reported that ASCs,
umbilical cord blood-derived MSCs, and BM-MSCs do not
induce allogeneic PBMC activation and proliferation in vitro
even if they express MHC-II [1, 20, 40, 41]. BM-MSCs stimu-
late mixed lymphocyte cultures and mitogenic responses inde-
pendently of MHC expression [41]. fMSCs that upregulate
HLA-II in response to IFN-c stimulation fail to induce an
immune response [21]. Therefore, the potential significance of
the lack or low expression of HLA-II in human iPSC-MSCs in
response to IFN-c stimulation should be carefully further
investigated. However, our study provides strong evidence
that there is no expression of HLA-II molecules in human
iPSC-MSCs under simulated inflammation conditions, which
are represented by IFN-c stimulation.
Moreover, adult MSCs, such as BM-MSCs, exhibit limited
proliferative capacity and a rapid loss of differentiation poten-
tial [42–44]. iPSCs are unspecialized cells that are capable of
renewing themselves infinitely in a culture dish, which allows
them to serve as an unlimited and noninvasive resource of
MSCs [13]. iPSC-MSCs have the potential to resolve the bot-
tleneck problem that BM-MSCs are not sufficiently able to
expand to the numbers needed for clinical use due to the
long and complicated procedure and their limited proliferative
activity. Our data suggest that iPSC-MSCs exhibited some dif-
ference or advantages compared to BM-MSCs even they had
almost similar morphology, surface markers, and therapeutic
effects. We previously found that there was a nearly 10-fold
higher level of telomerase activity in iPSC-MSCs than in BM-
MSCs [13]. This may explain our finding that the greater
capacity of cell proliferation in iPSC-MSCs than BM-MSCs [13].
Although protein levels of pluripotency-associated genes were
undetected in iPSC-MSCs and they did not induce any tumor
formation after 4 months after subcutaneously transplanting
into severe combined immunodeficiency mice [13], the safety
Figure 7. Diagram of the signaling pathways involved in the
induction of HLA-II molecules in human iPSC-MSCs. In human
iPSC-MSCs, IFN-cR1 and IFN-cR2 were maintained at low levels
even after stimulation with IFN-c. A low amount of STAT1 is phos-
phorylated, and thus few dimerized p-STAT1 molecules are avail-
able. In addition, these cells exhibit low IRF-1 and CIITA
expression levels. Low levels of CIITA are transcripted due to the
low level of IRF-1 and the low number of p-STAT1 dimers. Conse-
quently, there is an insufficient amount of CIITA proteins to
induce the expression of HLA-II molecules. Human iPSC-MSCs
express low levels of HLA-II molecules in response to IFN-c stimu-
lation. Abbreviations: CIITA, class II transactivator; IFN-c, inter-
feron-c; iPSC, induced pluripotent stem cell; IRF-1, interferon
regulatory factor 1; MSC, mesenchymal stem cell; STAT1, the sig-
nal transducer and activator of transcription 1.
14 Low Expression of HLA Molecules in iPSC-MSCs
VC 2015 The Authors. STEM CELLS published by Wiley Periodicals, Inc. on behalf of AlphaMed Press STEM CELLS
concern associated with the genomic instability of iPSCs still
should be carefully evaluated before the clinical translation of
iPSC-MSCs [45, 46].
Human iPSC-MSCs are immunosuppressive and poorly
immunogenic, and these features make them attractive candi-
dates as therapeutic agents in transplantation approaches for
the treatment of diseases characterized by an abnormal acti-
vation of the immune system, such as GvHD. The combination
of the proliferative capacity of human iPSC-MSCs and the
immunological inertness of these cells indicates that they may
be a source for more easily derived and highly acceptable
MSCs that can be obtained at a higher yield.
CONCLUSION
In summary, we demonstrated that human iPSC-MSCs are
insensitive to proinflammatory IFN-c-induced HLA-II expression
and have a stronger immune privilege after transplantation.
This may contribute to a better therapeutic efficacy in alloge-
neic transplantation.
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